文献詳細
特集 どうする! 前立腺癌―多彩な治療薬をどう上手く使うか
〈mCRPCの薬物治療〉
文献概要
▶ポイント
・骨転移を認める去勢抵抗性前立腺癌(CRPC)に対してRa-223は全生存期間を延長する薬剤である.
・Ra-223は使用タイミングを意識しないと使うタイミングを逃してしまうことが多い.
・6回完遂することが重要である.
・骨転移を認める去勢抵抗性前立腺癌(CRPC)に対してRa-223は全生存期間を延長する薬剤である.
・Ra-223は使用タイミングを意識しないと使うタイミングを逃してしまうことが多い.
・6回完遂することが重要である.
参考文献
1) Hoskin P, et al : Efficacy and Safety of Radium-223 Dichloride in Patients with Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases, with or without Previous Docetaxel Use : A Prespecified Subgroup Analysis from the Randomised, Double-Blind, Phase 3 ALSYMPCA Trial. Lancet Oncol 15 : 1397-1406, 2014
2) Kawahara T, et al : Administration of Radium-223 and the Prognosis in Japanese Bone Metastatic Castration-Resistant Prostate Cancer Patients : A Large Database Study. Int J Urol 29 : 1079-1084, 2022
3) Halabi S, et al : Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol 34 : 1652-1659, 2016
4) Ryan CJ, et al : Abiraterone Acetate plus Prednisone versus Placebo plus Prednisone in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer (COU-AA-302) : Final Overall Survival Analysis of a Randomised, Double-Blind, Placebo-Controlled Phase 3 Study. Lancet Oncol 16 : 152-160, 2015
5) Fizazi K, et al : Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer : Final Overall Survival Analysis of the COU-AA-301 Randomised, Double-Blind, Placebo-Controlled Phase 3 Study. Lancet Oncol 13 : 983-992, 2012
6) Beer TM, et al : Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol 71 : 151-154, 2017
7) Scher HI, et al : Increased Survival with Enzalutamide in Prostate Cancer After Chemotherapy. N Engl J Med 367 : 1187-1197, 2012
8) Smith MR, et al : Darolutamide and Health-Related Quality of Life in Patients with Non-Metastatic Castration-Resistant Prostate Cancer : An Analysis of the Phase III ARAMIS Trial. Eur J Cancer 154 : 138-146, 2021
9) Chi KN, et al : Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 381 : 13-24, 2019
掲載誌情報